A distinguished Professor and the Vice Chair of Research in the Department of Surgery at the Uniformed Services University (USU), Dr. Thomas A. Davis joined the institution in February 2017. He brings over 45 years of extensive expertise spanning immune modulation, immunotherapy, radiation injury, stem cell research, experimental hematology, wound healing, and transplantation biology. Throughout his career, Dr. Davis has maintained a central focus on the intricate mechanisms underlying acute cellular and organ injury in inflammatory conditions such as shock, trauma, and sepsis. His current laboratory research program encompasses two primary and interconnected areas: understanding the early inflammatory response to trauma and developing innovative regenerative tissue therapies.

Elucidating the Innate Immune Response to Traumatic Injury: Dr. Davis's past and current investigations rigorously examine the fundamental innate immune mechanisms activated following acute cellular and organ damage caused by traumatic injury. His research group is dedicated to elucidating the initiation of post-traumatic inflammatory cascades. To dissect these complex biological processes, his laboratory strategically employs diverse in vivo models, including controlled organ ischemia-reperfusion and systemic injury paradigms such as blast-induced trauma, hemorrhagic shock, thermal burns, and severe musculoskeletal trauma. Through meticulous analyses, his team characterizes key inflammatory mediators, delineates the downstream immunological sequelae of injury and inflammation, unravels mechanisms of organ dysfunction, and leverages genome-wide approaches to provide comprehensive insights into the molecular landscape of trauma-induced pathology.

Advancing Regenerative Tissue Approaches: A significant focus of Dr. Davis's laboratory is the development of innovative regenerative tissue approaches to address the debilitating sequelae of traumatic injury. His team pioneers strategies for the preservation, repair, regeneration, augmentation, or replacement of damaged musculoskeletal tissues. This includes the advancement and rigorous evaluation of novel cell-based therapies aimed at treating conditions such as heterotopic ossification, critical tissue loss (encompassing fractures, osteoporosis, and muscle atrophy), and cartilage defects. Furthermore, his research group is establishing groundbreaking methodologies and standards for the quantitative assessment of stem and progenitor cell populations within diverse tissues. These advancements are poised to transform the landscape of cell and gene therapy by providing critical tools for evaluating tissue health and disease progression, thereby enabling the development of precisely targeted cell-based interventions for trauma-related musculoskeletal pathologies. The overarching objective of Dr. Davis's research program is to fundamentally understand disease mechanisms and translate these insights into effective regenerative therapies.

Dr. Davis's wide-ranging research interests, supported by funding from the Department of Defense and USUHS, encompass stem cell biology, musculoskeletal trauma, heterotopic ossification, muscle fibrosis, tissue regeneration, osseointegration, wound healing and repair, traumatic brain injury (TBI), and combat-related prolonged field care outcomes. A prolific scholar, he is the author of more than 145 peer-reviewed articles and has presented his work at conferences worldwide. Additionally, he serves as an ad hoc reviewer for numerous leading journals in his fields of expertise, underscoring his significant contributions and standing within the scientific community.

Traumatic injury, blast injury, systemic inflammation and molecular signaling,  ischemia reperfusion injury, multiple organ dysfunction,  wound healing, heterotopic ossification,  innate immune response, tissue regeneration, tolerance induction